A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer

Oncogene

Volumn 31, Issue 6, 2012, Pages 716-727

  Rao, S ^a   Lyons, L S ^b   Fahrenholtz, C D ^a   Wu, F ^a   Farooq, A ^a   Balkan, W ^a   Burnstein, K L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

androgen receptor; castration resistant prostate cancer; coactivator; guanine nucleotide exchange factor; pleckstrin homology; Vav3

Indexed keywords

ANDROGEN RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PLECKSTRIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN VAV3; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GRAFT; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CASTRATION; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CYTOPLASM; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; TUMOR GROWTH;

ANIMALS; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CYTOPLASM; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; METRIBOLONE; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; MUTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-VAV; RECEPTORS, ANDROGEN; TRANS-ACTIVATORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84856955553     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.273     Document Type: Article

References (56)

1. Balk SP. (2002). Androgen receptor as a target in androgen-independent prostate cancer. Urology 60: 132-138; discussion 138-139.
2. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn J et al. (2007). Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 67: 9089-9096. (Pubitemid 47535894)
3. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. (2001). Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 276: 48679-48692.
4. Brantley-Sieders DM, Zhuang G, Vaught D, Freeman T, Hwang Y, Hicks D et al. (2009). Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Mol Cancer Res 7: 615-623.
5. Bustelo XR. (2001). Vav proteins, adaptors and cell signaling. Oncogene 20: 6372-6381. (Pubitemid 32977845)
6. Carson M. (1991). Ribbons 2.0. J Appl Crystallogr 24: 958-961.
7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39. (Pubitemid 38524696)
8. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH et al. (2006). Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 20: 2315-2325. (Pubitemid 44496404)
9. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R et al. (2005). Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7: 39-49. (Pubitemid 40126381)
10. Franke TF, Kaplan DR, Cantley LC, Toker A. (1997). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-668. (Pubitemid 27061333)
11. Fujikawa K, Miletic AV, Alt FW, Faccio R, Brown T, Hoog J et al. (2003). Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med 198: 1595-1608. (Pubitemid 37467173)
12. He B, Gampe Jr RT, Kole AJ, Hnat AT, Stanley TB, An G et al. (2004). Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16: 425-438. (Pubitemid 39504796)
13. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. (1999). Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274: 37219-37225.
14. He B, Lee LW, Minges JT, Wilson EM. (2002). Dependence of selective gene activation on the androgen receptor NH2-and COOH-terminal interaction. J Biol Chem 277: 25631-25639. (Pubitemid 34951881)
15. Heery DM, Kalkhoven E, Hoare S, Parker MG. (1997). A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736. (Pubitemid 27270617)
16. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L et al. (2004). Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217-227. (Pubitemid 38364606)
17. Hornstein I, Pikarsky E, Groysman M, Amir G, Peylan-Ramu N, Katzav S. (2003). The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. J Pathol 199: 526-533. (Pubitemid 36411229)
18. Houlard M, Arudchandran R, Regnier-Ricard F, Germani A, Gisselbrecht S, Blank U et al. (2002). Vav1 is a component of transcriptionally active complexes. J Exp Med 195: 1115-1127. (Pubitemid 34517138)
19. Jaffe AB, Hall A. (2005). Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21: 247-269. (Pubitemid 41740635)
20. John B, Sali A. (2003). Comparative protein structure modeling by iterative alignment, model building and model assessment. Nucleic Acids Res 31: 3982-3992. (Pubitemid 37442277)
21. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R et al. (2001). VCaP, a cell-based model system of human prostate cancer. In vivo 15: 163-168. (Pubitemid 32328191)
22. Lemmon MA. (1999). Structural basis for high-affinity phosphoinositide binding by pleckstrin homology domains. Biochem Soc Trans 27: 617-624.
23. Lemmon MA. (2003). Phosphoinositide recognition domains. Traffic 4: 201-213.
24. Lemmon MA. (2004). Pleckstrin homology domains: not just for phosphoinositides. Biochem Soc Trans 32: 707-711.
25. Lemmon MA. (2007). Pleckstrin homology (PH) domains and phosphoinositides. Biochem Soc Symp 74: 81-93.
26. Lemmon MA. (2008). Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 9: 99-111.
27. Lemmon MA, Ferguson KM. (2000). Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochem J 350 (Part 1): 1-18.
28. Lemmon MA, Ferguson KM. (2001). Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides. Biochem Soc Trans 29: 377-384. (Pubitemid 32783622)
29. Lemmon MA, Ferguson KM, Abrams CS. (2002). Pleckstrin homology domains and the cytoskeleton. FEBS Lett 513: 71-76. (Pubitemid 34242981)
30. Liu Y, Mo JQ, Hu Q, Boivin G, Levin L, Lu S et al. (2008). Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res 68: 6396-6406.
31. Liu Y, Wu X, Dong Z, Lu S. (2010). The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells. Int J Oncol 36: 623-633.
32. Lopez-Lago M, Lee H, Cruz C, Movilla N, Bustelo XR. (2000). Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav. Mol Cell Biol 20: 1678-1691. (Pubitemid 30100187)
33. Lyons LS, Burnstein KL. (2006). Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 20: 1061-1072.
34. Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. (2008). Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol 22: 597-608. (Pubitemid 351397788)
35. Maffucci T, Razzini G, Ingrosso A, Chen H, Iacobelli S, Sciacchitano S et al. (2003). Role of pleckstrin homology domain in regulating membrane targeting and metabolic function of insulin receptor substrate 3. Mol Endocrinol 17: 1568-1579. (Pubitemid 36930471)
36. Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S et al. (2008). Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther 7: 2621-2632.
37. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. (2010). Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 5: e13500.
38. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. (2000). Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291-325. (Pubitemid 30599596)
39. Miller SL, DeMaria JE, Freier DO, Riegel AM, Clevenger CV. (2005). Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol 19: 939-949.
40. Mohler JL, Gregory CW, Ford III OH, Kim D, Weaver CM, Petrusz P et al. (2004). The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448. (Pubitemid 38173980)
41. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
42. Movilla N, Bustelo XR. (1999). Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol 19: 7870-7885. (Pubitemid 29493450)
43. O'Malley BW, Kumar R. (2009). Nuclear receptor coregulators in cancer biology. Cancer Res 69: 8217-8222.
44. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ et al. (2008). Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 68: 2132-2144. (Pubitemid 351521785)
45. Palmby TR, Abe K, Der CJ. (2002). Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity. J Biol Chem 277: 39350-39359. (Pubitemid 35190908)
46. Patel V, Rosenfeldt HM, Lyons R, Servitja JM, Bustelo XR, Siroff M et al. (2007). Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion. Carcinogenesis 28: 1145-1152. (Pubitemid 47062672)
47. Rapley J, Tybulewicz VL, Rittinger K. (2008). Crucial structural role for the PH and C1 domains of the Vav1 exchange factor. EMBO Rep 9: 655-661. (Pubitemid 351927686)
48. Savkur RS, Burris TP. (2004). The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 63: 207-212. (Pubitemid 38496672)
49. Schmidt LJ, Regan KM, Anderson SK, Sun Z, Ballman KV, Tindall DJ. (2009). Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate 69: 1730-1743.
50. Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD et al. (2005). GRIP1 mediates the interaction between the amino-and carboxyl-termini of the androgen receptor. Biol Chem 386: 69-74. (Pubitemid 40361453)
51. Tindall DJ, Scardino PJ. (2001). State of research for prostate cancer: excerpt from the report of the Prostate Cancer Progress Review Group. Urology 57: 28-30.
52. Trenkle T, McClelland M, Adlkofer K, Welsh J. (2000). Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene 245: 139-149. (Pubitemid 30125373)
53. Varnai P, Bondeva T, Tamas P, Toth B, Buday L, Hunyady L et al. (2005). Selective cellular effects of overexpressed pleckstrin-homology domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein binding partners. J Cell Sci 118: 4879-4888. (Pubitemid 41646394)
54. Wang Q, Carroll JS, Brown M. (2005). Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol cell 19: 631-642. (Pubitemid 41219439)
55. Xi S, Tie Y, Lu K, Zhang M, Yin X, Chen J et al. (2010). N-terminal PH domain and C-terminal auto-inhibitory region of CKIP-1 coordinate to determine its nucleus-plasma membrane shuttling. FEBS Lett 584: 1223-1230.
56. Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M et al. (2000). Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 20: 9212-9224. (Pubitemid 32246108)